BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 38612910)

  • 21. Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma.
    Brigliadori G; Goffredo G; Bartolini D; Tosatto L; Gurrieri L; Mercatali L; Ibrahim T
    Front Oncol; 2020; 10():533000. PubMed ID: 33194592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.
    Han S; Liu Y; Cai SJ; Qian M; Ding J; Larion M; Gilbert MR; Yang C
    Br J Cancer; 2020 May; 122(11):1580-1589. PubMed ID: 32291392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms.
    Kessler J; Hohmann T; Güttler A; Petrenko M; Ostheimer C; Hohmann U; Bache M; Dehghani F; Vordermark D
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31242696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TLR-4/Wnt modulation as new therapeutic strategy in the treatment of glioblastomas.
    Casili G; Caffo M; Campolo M; Barresi V; Caruso G; Cardali SM; Lanza M; Mallamace R; Filippone A; Conti A; Germanò A; Cuzzocrea S; Esposito E
    Oncotarget; 2018 Dec; 9(101):37564-37580. PubMed ID: 30680070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ki-67 labeling index in glioblastoma; does it really matter?
    Alkhaibary A; Alassiri AH; AlSufiani F; Alharbi MA
    Hematol Oncol Stem Cell Ther; 2019 Jun; 12(2):82-88. PubMed ID: 30552865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
    Ostrom QT; Gittleman H; Truitt G; Boscia A; Kruchko C; Barnholtz-Sloan JS
    Neuro Oncol; 2018 Oct; 20(suppl_4):iv1-iv86. PubMed ID: 30445539
    [No Abstract]   [Full Text] [Related]  

  • 28. Modulation of Dkk-3 and claudin-5 as new therapeutic strategy in the treatment of meningiomas.
    Caffo M; Esposito E; Barresi V; Caruso G; Cardali SM; Rinaldi M; Mallamace R; Campolo M; Casili G; Conti A; Germanò A; Cuzzocrea S; Minutoli L
    Oncotarget; 2017 Sep; 8(40):68280-68290. PubMed ID: 28978116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Putting p53 in Context.
    Kastenhuber ER; Lowe SW
    Cell; 2017 Sep; 170(6):1062-1078. PubMed ID: 28886379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. WNT signaling in glioblastoma and therapeutic opportunities.
    Lee Y; Lee JK; Ahn SH; Lee J; Nam DH
    Lab Invest; 2016 Feb; 96(2):137-50. PubMed ID: 26641068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
    Wickström M; Dyberg C; Milosevic J; Einvik C; Calero R; Sveinbjörnsson B; Sandén E; Darabi A; Siesjö P; Kool M; Kogner P; Baryawno N; Johnsen JI
    Nat Commun; 2015 Nov; 6():8904. PubMed ID: 26603103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status.
    Kessler J; Güttler A; Wichmann H; Rot S; Kappler M; Bache M; Vordermark D
    Radiother Oncol; 2015 Sep; 116(3):381-7. PubMed ID: 26328938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis.
    Chen WJ; He DS; Tang RX; Ren FH; Chen G
    Asian Pac J Cancer Prev; 2015; 16(2):411-20. PubMed ID: 25684464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting TP53 Mutations and Immunohistochemistry--A Comparative Study in 157 Diffuse Gliomas.
    Takami H; Yoshida A; Fukushima S; Arita H; Matsushita Y; Nakamura T; Ohno M; Miyakita Y; Shibui S; Narita Y; Ichimura K
    Brain Pathol; 2015 May; 25(3):256-65. PubMed ID: 25040820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense oligonucleotides in the treatment of cerebral gliomas. Review of concerning patents.
    Caruso G; Caffo M
    Recent Pat CNS Drug Discov; 2014 Apr; 9(1):2-12. PubMed ID: 24605941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.
    De Robertis A; Valensin S; Rossi M; Tunici P; Verani M; De Rosa A; Giordano C; Varrone M; Nencini A; Pratelli C; Benicchi T; Bakker A; Hill J; Sangthongpitag K; Pendharkar V; Liu B; Ng FM; Then SW; Jing Tai S; Cheong SM; He X; Caricasole A; Salerno M
    Mol Cancer Ther; 2013 Jul; 12(7):1180-9. PubMed ID: 23619303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
    Gao J; Aksoy BA; Dogrusoz U; Dresdner G; Gross B; Sumer SO; Sun Y; Jacobsen A; Sinha R; Larsson E; Cerami E; Sander C; Schultz N
    Sci Signal; 2013 Apr; 6(269):pl1. PubMed ID: 23550210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.
    Yan W; Zhang W; You G; Bao Z; Wang Y; Liu Y; Kang C; You Y; Wang L; Jiang T
    PLoS One; 2012; 7(1):e30339. PubMed ID: 22291938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
    Fasching PA; Heusinger K; Haeberle L; Niklos M; Hein A; Bayer CM; Rauh C; Schulz-Wendtland R; Bani MR; Schrauder M; Kahmann L; Lux MP; Strehl JD; Hartmann A; Dimmler A; Beckmann MW; Wachter DL
    BMC Cancer; 2011 Nov; 11():486. PubMed ID: 22081974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.